

SGLT2 INHIBITORS: THE NEW WONDER DRUGS IN CARDIOLOGY?

Going beyond glycemic control

BEST PRACTICES FORUM



WEDNESDAY, APRIL 14, 2021



8:00 – 9:00 PM EST

DESCRIPTION:

A case-based discussion on SGLT2 inhibition for glycemic control and newer indications such as heart failure prevention, treatment, and management of chronic kidney disease

AGENDA:

- 8:00 PM** Opening Comments
Milan Gupta
- 8:05 PM** Overview of class benefits in patients with diabetes at high CV risk - Robyn Houlden
- 8:21 PM** Interplay between diabetes, heart failure, and kidney disease - David Cherney
- 8:37 PM** Latest clinical trial results with SGLT2 inhibitors in heart failure - Milan Gupta
- 8:53 PM** Latest clinical trial results with SGLT2 inhibitors in CKD
David Cherney
- 9:09 PM** Case-based examples and discussion
Peter Lin
- 9:29 PM** Closing comments
Milan Gupta

OUR SPEAKERS



Dr. Milan Gupta,
Program Chair
Cardiology,
Brampton, ON



Dr. David Cherney,
Nephrology,
Toronto, ON



Dr. Robyn Houlden,
Endocrinology,
Kingston, ON



Dr. Peter Lin,
Primary Care,
Toronto, ON



Registration: www.ccrnmd.com
For program inquiries, contact info@ccrnmd.com



This program was developed by the Canadian Collaborative Research Network and received an unrestricted educational grant from AstraZeneca and Janssen.